Three policy wonks dissect President Donald Trump’s executive orders on border security, immigration, government efficiency ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the ...
Understanding the distinction between eligible and non-eligible dividends is vital due to their different tax treatments by the Canada Revenue Agency (CRA ... subject to a form of double taxation ...
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency ...
Kidney cancer therapy candidate, TLX250 (177Lu-girentuximab): The Company was granted a pre-investigational new drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) in Q4 2024, to ...
For example, the Canada child benefit (CCB ... described on our page on a permanent basis and meet the other conditions, make sure you complete Form T2222 to save money on your taxes. Residents of the ...
In order to receive, or continue to receive, benefit and credit payments, individuals have to update their information with the Canada Revenue Agency (CRA ... There are no complex forms to fill out or ...
The president ordered the withdrawal of the country from the Paris climate agreement and took action on immigration policy ...
( MENAFN - EIN Presswire) 2024 was an active year for environmental, social and governance (ESG) regulations, voluntary reporting standards, and stakeholder policies. While the incoming trump ...
If granted marketing authorization, trofinetide will be the first and only approved therapy for Rett syndrome in the European Union (EU). Trofinetide is already approved in the United States and ...
The Company will file a Current Report on Form 8-K with additional details regarding the ... or subscribe for any securities or the solicitation of a proxy, consent, or authorization in any ...